BURNABY, British Columbia, July 13, 2021 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced its participation in a virtual fireside chat at the William Blair Biotech Focus Conference 2021.
| Date: | Thursday, July 15, 2021 |
| Time: | 10 am – 10:45 am Eastern Time |
| Participants: | Ian Mortimer, President and CEO | Dr. Simon Pimstone, Executive Chair of the Board |
Additional details along with a link to the live webcast can be found on the “Investors” section of Xenon’s website at http://investor.xenon-pharma.com. When available, webcasts will be posted for replay following the event for 30 days. The above listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Investor/Media Contact:
Maria McClean
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: investors@xenon-pharma.com
New ticker symbol, “FEED” will begin trading on the Nasdaq at the open of the…
TAMPA, Fla.--(BUSINESS WIRE)--Smart Meter, the leader in Cellular RPM™ and the nation’s most trusted source…
AUSTIN, Texas--(BUSINESS WIRE)--#CognitiveHealth--BrainCheck, the leading FDA Class II digital cognitive assessment and care platform, has…
SAN JOSE, CALIFORNIA / ACCESS Newswire / December 12, 2025 / VSee Health, Inc. (Nasdaq:VSEE,…
Industry leader recognized for excellence and innovation in clinical developmentRALEIGH, N.C., Dec. 12, 2025 (GLOBE…
The European Medicines Agency (EMA) has issued a positive opinion for a new Wegovy® 7.2…